Table 1.
Baseline characteristics of female RA patients treated with TNFαI
| Characteristic | Value |
|---|---|
| All women with RA, n (%) | 45 (100) |
| Age (years), mean (SD) | 47.42 (13.70) |
| Disease duration (years), median (IQR) | 7 (4–16) |
| BMI (kg/m2), mean (SD) | 21.99 (2.26) |
| RF positive, n (%) | 44 (97.78) |
| Anti-CCP positive, n (%) | 45 (100) |
| SJC28, median (IQR) | 8 (5–10) |
| TJC28, median (IQR) | 14 (10–19) |
| VAS, median (IQR) | 80 (80–80) |
| DAS28 ESR, mean (SD) | 6.10 (0.58) |
| ESR (mm/h), median (IQR) | 18.0 (11.0–33.0) |
| CRP (mg/l), median (IQR) | 5.0 (4.0–14.9) |
| TNFαI therapy, n (%) | |
| Etanercept (Enbrel) | 19 (42.22) |
| Adalimumab (Humira) | 22 (48.89) |
| Certolizumab pegol (Cimzia) | 4 (8.89) |
anti-CCP anti-cyclic citrullinated peptide antibody, BMI body mass index, CRP C-reactive protein, DAS28 Disease Activity Score based on evaluation of 28 joints, ESR erythrocyte sedimentation rate, IQR interquartile range, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SJC28 swollen joint count of 28 joints, TJC28 tender joint count of 28 joints, TNFαI tumor necrosis factor-alpha inhibitors, VAS visual analog scale